Current therapy for condylomata acuminata (genital warts) is not consistently effective. Therefore, we conducted a randomized, double-blind trial to compare interferon alpha-2b with placebo in the treatment of this disorder. Our rationale was that interferon has both antiproliferative and antiviral properties. The placebo or interferon (1 X 10(6) IU) was injected directly into one to three warts three times weekly for three weeks. The injections were well tolerated by both groups of patients. The side effects of fever, chills, myalgia, headache, fatigue, and leukopenia occurred more commonly in the interferon group than in the placebo group, but such effects rarely disrupted daily routines. Only 13 of 296 patients (4 percent) discontinued therapy because of side effects (11 in the interferon group and 2 in the placebo group). Twenty-six other patients were excluded from analysis because of a loss to follow-up or other deviations from protocol, thus leaving 257 patients in the final evaluation. At one week after the completion of therapy, interferon had produced a large and significantly greater reduction in mean wart area (a 62.4 percent decrease), as compared with placebo (a 1.2 percent increase in mean area) (P less than 0.001). At the conclusion of the study (13 weeks after the completion of therapy), the mean wart area was still decreased 39.9 percent below the initial size in the interferon group, whereas it had increased by 46 percent over base-line measurements in the placebo group (P less than 0.001). At the same time, all treated warts had completely cleared in 36 percent of the interferon recipients and in 17 percent of the placebo recipients (P less than 0.001), whereas treated warts progressed in 13 percent of the interferon recipients and in 50 percent of the placebo recipients (P less than 0.001). We conclude that injection of interferon alpha-2b directly into genital warts appears to be an effective and fairly well-tolerated form of therapy.
This article has been cited by other articles:
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Beutner, K. R., Tyring, S. K., Trofatter, K. F. Jr., Douglas, J. M. Jr., Spruance, S., Owens, M. L., Fox, T. L., Hougham, A. J., Schmitt, K. A.
(1998). Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts. Antimicrob. Agents Chemother.
42: 789-794
[Abstract][Full Text]
Edwards, L., Ferenczy, A., Eron, L., Baker, D., Owens, M. L., Fox, T. L., Hougham, A. J., Schmitt, K. A., and the HPV Study Group,
(1998). Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts. Arch Dermatol
134: 25-30
[Abstract][Full Text]
Ficarra, G., Shillitoe, E.J.
(1992). HIV-Related Infections of the Oral Cavity. CROBM
3: 207-231
[Abstract][Full Text]
Gross, G.
(1991). Recombinant Interferon Gamma in Condylomata Acuminata. JAMA
266: 2706-2706
[Abstract]
Condylomata International Collaborative Study Grou,
(1991). Recurrent Condylomata Acuminata Treated With Recombinant Interferon Alfa-2a: A Multicenter Double-blind Placebo-Controlled Clinical Trial. JAMA
265: 2684-2687
[Abstract]
Gorman, S. E., Plaisance, K.
(1991). Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice
4: 103-116
Beutner, K. R.
(1990). Bridging the Gap: Notes of a Wart Watcher. Arch Dermatol
126: 1432-1435
[Abstract]
Magee, K. L., Hsu, S.-M., Tucker, S. B.
(1990). Trial of Intralesional Interferon Alfa in the Treatment of Alopecia Areata. Arch Dermatol
126: 760-762
[Abstract]
REICHMAN, R. C., OAKES, D., BONNEZ, W., GREISBERGER, C., TYRING, S., MILLER, L., WHITLEY, R., CARVETH, H., WEIDNER, M., KRUEGER, G., YORKEY, L., ROBERTS, N. J. Jr., DOLIN, R.
(1988). Treatment of Condyloma Acuminatum with Three Different Interferons Administered lntralesionally: A Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
108: 675-679
[Abstract]
Friedman-Kien, A. E., Eron, L. J., Conant, M., Growdon, W., Badiak, H., Bradstreet, P. W., Fedorczyk, D., Trout, J. R., Plasse, T. F.
(1988). Natural Interferon Alfa for Treatment of Condylomata Acuminata. JAMA
259: 533-538
[Abstract]
Kirby, P.
(1988). Interferon and Genital Warts: Much Potential, Modest Progress. JAMA
259: 570-572
[Abstract]
Steinberg, B. M., Gallagher, T., Stoler, M., Abramson, A. L.
(1988). Persistence and Expression of Human Papillomavirus During Interferon Therapy. Arch Otolaryngol Head Neck Surg
114: 27-32
[Abstract]
Edwards, L.
(1987). Interferon: Promises, Disappointments, and Tempered Optimism. Arch Dermatol
123: 743-744
[Abstract]
FAHEY, J. L., SARNA, G., GALE, R. P., SEEGER, R.
(1987). Immune Interventions in Disease. ANN INTERN MED
106: 257-274
[Abstract]
Previous
